Contract negotiations between Mount Sinai and Anthem Blue Cross Blue Shield broke down this week, leaving the health system completely out of Anthem’s insurance network. The dispute reflects broader ...

Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...

Grow Therapy's Series D funding was led by TCV and Growth Equity at Goldman Sachs Alternatives, with participation from BCI, Menlo Ventures, Sequoia, SignalFire and Transformation Capital.

Health data company Health Gorilla filed a motion to dismiss a lawsuit from Epic and several healthcare providers alleging inappropriate access to nearly 300,000 patient records. The case highlights ...

After Congress failed to pass a funding bill, the government shut down early Wednesday morning, which has significant implications for healthcare, including the future of telehealth flexibilities and ...

In the past couple of years, payers have come under scrutiny as they increasingly adopt AI tools to automate tasks like the claims review and prior authorization requests. Providers have voiced ...

This roundup is published monthly. It is meant to highlight some of healthcare’s recent hiring news and is not intended to be comprehensive. If you have news about an executive appointment, ...

On April 24, the Centers for Medicare and Medicaid Services announced plans to overhaul the Meaningful Use program by turning to a focus on interoperability. Thus, it only makes sense that the agency ...

The FDA turned down an Intercept Pharmaceuticals drug application for the fatty liver disease NASH, a decision that comes nearly three years after the regulator first rejected the molecule. The agency ...

Eli Lilly’s engineered peptide drugs Mounjaro and Zepbound are once-weekly injectable products, formulations that are expensive to manufacture and burdensome to patients who dislike needles. Lilly ...

Otsuka Pharmaceutical is broadening its scope in rare disease, striking a deal to acquire Jnana Therapeutics and its lead drug candidate, a small molecule on track for pivotal testing in a metabolic ...